Drug Profile
TLX591 companion diagnostic - Telix Pharmaceuticals
Alternative Names: 68Ga PSMA-11 - Telix Pharmaceuticals; 68Ga-HBED-CC-PSMA - Advanced Nuclear Medicine Ingredients; 68Ga-HBED-iPSMA PET; 68Ga-PSMA-11 - Advanced Nuclear Medicine Ingredients; 68Ga-PSMA-IRDye; 68Ga-PSMA-IRDye - Telix Pharmaceuticals; 68Ga PSMA-11 injection; Ga-68 gozetotide injection - Telix Pharmaceuticals; gallium-68 (68Ga) gozetotide injection - Telix Pharmaceuticals; Glu-urea-Lys(ahx)-hbed-CC; Illuccix; illumet; TLX 591CDx; TLX-591 companion diagnostic - Advanced Nuclear Medicine Ingredients/Telix Pharmaceuticals; TLX591-Cdx - Advanced Nuclear Medicine Ingredients/Telix Pharmaceuticals; TLX591-Sx; TLX591-Sx - Telix PharmaceuticalsLatest Information Update: 15 Dec 2023
Price :
$50
*
At a glance
- Originator Advanced Nuclear Medicine Ingredients
- Developer Emory University; Kanazawa University; Telix Pharmaceuticals
- Class Antineoplastics; Diagnostic agents; Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Prostate cancer
- Phase I Breast cancer
Most Recent Events
- 08 Nov 2023 WIIK Pharma and Telix Pharmaceuticals enter into a distribution agreement for the distribution of Illuccix® in the Nordic region
- 20 Oct 2023 Telix Pharmaceuticals plans the commercial launch for TLX591 companion diagnostic for Renal cancer (Diagnosis) and Brain cancer (Diagnosis)
- 18 Oct 2023 Telix Pharmaceuticals completes pre-NDA meeting with the Pharmaceuticals and Medical Devices Agency (PMDA) for a regulatory filling for Illuccix in Japan